VitalHub - President and CEO, Dan Matlow
President and CEO, Dan Matlow
Source: Small Cap Power
  • VitalHub has received conditional approval to uplist its common shares from the TSXV to the TSX
  • VitalHub will be de-listed from the TSXV
  • VitalHub will issue a press release once the TSX confirms the date when VitalHub common shares will commence trading on the TSX
  • Vitalhub Corp is Canadian-based firm that develops technology solutions for health and human services providers 
  • Vitalhub Corp. (VHI) opened trading at C$3.16 per share

VitalHub (VHI) has received conditional approval to list its common shares on the TSX.

VitalHub will be de-listed from the TSXV.

VitalHub CEO Dan Matlow commented on the approval to uplist.

“Receiving approval and uplisting to the TSX marks another step forward in our journey toward cementing our internationally recognized leadership role within the healthcare IT sector. VitalHub’s solutions are used by over 300 customers across five countries, with many of our offerings viewed as leading solutions across international jurisdictions. Our growth through synergistic M&A combined with our strong organic expansion has created the foundation required for continued, scalable growth well into the future. Uplisting to the TSX will serve to increase the potential depth of our investor base on a go-forward basis, as we continue to execute on our strategy, and will undoubtedly benefit our investors, customers, and employees.

Congratulations and thanks to all who have been involved.”

VitalHub will issue a press release once the TSX confirms the date when VitalHub common shares will commence trading on the TSX.

VitalHub provides technology to Health and Human Services providers including; Hospitals, Regional Health Authorities, Mental Health, Long Term Care, Home Health, Community and Social Services.

Vitalhub Corp. (VHI) opened trading at C$3.16 per share.

More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.